Serial monitoring of LV function following chemotherapy: assessment using advanced echocardiography and cardiovascular magnetic resonance by Suchi Grover et al.
POSTER PRESENTATION Open Access
Serial monitoring of LV function following
chemotherapy: assessment using advanced
echocardiography and cardiovascular magnetic
resonance
Suchi Grover1,3*, Rebecca Perry1,2, Darryl Leong1, Majo Joseph2, Bogda Koczwara4, Joseph Selvanayagam1,3
From 17th Annual SCMR Scientific Sessions
New Orleans, LA, USA. 16-19 January 2014
Background
Patients receiving anthracyclines (A) and herceptin (H)
for treatment of breast cancer require serial monitoring
of LV function. Although CMR is considered the gold
standard for assessment of volumes and function, most
tertiary institutions rely on echocardiography or gated
heart pool scans. 2D transthoracic echocardiographic
(TTE) image quality relies on appropriate acoustic win-
dows, and accuracy and reproducibility may be particu-
larly limited in this population due to mastectomy and
scar. We sought to assess the utility of TTE (LVEF and
GLS) compared to CMR in the diagnosis of Stage B
heart failure (defined as evidence of structural disease
but without signs and symptoms of heart failure [1]) in
breast cancer patients receiving cytotoxic chemotherapy.
Methods
In total, 44 patients (30 receiving A and 14 receiving T)
underwent cardiac magnetic resonance (CMR) for LV
function and advanced 2D echocardiography for LV
function and global longitudinal strain (GLS) at 3 time-
points (baseline, 3 months and 12 months). We defined
stage B heart failure as LVEF < 10% from baseline, and/
or LVEF below 55% and/or GLS < -19.7[2].
Results
CMR cine assessment of LV function was performed in
all 44 patients (100%). Thirty percent (13/44) could not
have accurate echocardiographic EF assessment per-
formed at 1 or more time points. Early LV dysfunction
was detected by CMR following commencement of che-
motherapy (table). There was poor correlation between
CMR LVEF and echocardiography EF (graph) with wide
limits of agreement (-23.526 to 13.015%). At 12 months,
8 patients (18%) demonstrated stage B heart failure, how-
ever none were below the lower limits of normal (>55%).
None of these showed a significant change in TTE EF,
however 2 of these patients had GLS < 19.7 at 12 months.
Conclusions
A significant number (approx. 1/3) of breast cancer
patients are unable to have adequate LV function assess-
ment by echocardiography. Subtle LV dysfunction may be
a precursor to overt cardiomyopathy and is currently not
adequately diagnosed by echocardiography even with
inclusion of 2D global longitudinal strain. Serial monitor-
ing of LV function using a non-radiation imaging techni-
que is best performed by CMR.
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Baseline 71.9 ± 6.3 63.8 ± 5.7 -21.4 ± 2.6
3 months 66.7 ± 6.7 ** 63.5 ± 7.2 -19.5 ± 2.0 **
12 months 65.9 ± 7.0 ** 62.1 ± .9 -20.1 ± 2.6
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